Bicara Therapeutics Inc.
BCAXUnited States
8 filed reports · 208 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
8 reports · Sep 2024 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 6 | 880 | Sep 2024 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 2 | 693 | Dec 2024 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 11, 2026 | 263 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 11, 2026 | 165 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 30, 2026 | 413 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 10, 2025 | 183 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 12, 2025 | 91 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 13, 2025 | 94 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 27, 2025 | 280 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 12, 2024 | 84 | Open |
Financial data
208 concepts · 1,573 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial195 concepts · 1,417 facts · Mar 2023 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value17 · Mar 2023 to Jun 2026
- Net income loss17 · Mar 2023 to Jun 2026
- Stockholders equity (US GAAP)17 · Mar 2023 to Jun 2026
- Stock issued during period value stock options exercised17 · Mar 2023 to Jun 2026
- Allocated share based compensation expense15 · Sep 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents15 · Sep 2023 to Jun 2026
- General and administrative expense (US GAAP)15 · Sep 2023 to Jun 2026
- Income tax expense benefit15 · Sep 2023 to Jun 2026
- Investment income interest15 · Sep 2023 to Jun 2026
- Nonoperating income expense15 · Sep 2023 to Jun 2026
- Operating expenses (US GAAP)15 · Sep 2023 to Jun 2026
- Operating income loss15 · Sep 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect14 · Dec 2023 to Jun 2026
- Common stock par or stated value per share14 · Dec 2023 to Jun 2026
- Common stock shares authorized14 · Dec 2023 to Jun 2026
- Depreciation14 · Dec 2023 to Jun 2026
- Increase decrease in operating lease liability14 · Dec 2023 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets14 · Dec 2023 to Jun 2026
- Net cash provided by used in financing activities14 · Dec 2023 to Jun 2026
- Net cash provided by used in investing activities14 · Dec 2023 to Jun 2026
- Net cash provided by used in operating activities14 · Dec 2023 to Jun 2026
- Payments to acquire property plant and equipment14 · Dec 2023 to Jun 2026
- Preferred stock par or stated value per share14 · Dec 2023 to Jun 2026
- Preferred stock shares authorized14 · Dec 2023 to Jun 2026
Segment13 concepts · 156 facts · Dec 2023 to Jun 2026
- General and administrative expense (US GAAP)13 · Dec 2023 to Jun 2026
- Income tax expense13 · Dec 2023 to Jun 2026
- Investment income interest13 · Dec 2023 to Jun 2026
- Net income loss13 · Dec 2023 to Jun 2026
- Nonoperating income expense13 · Dec 2023 to Jun 2026
- Operating expenses (US GAAP)13 · Dec 2023 to Jun 2026
- Operating income loss13 · Dec 2023 to Jun 2026
- Other research and development expense13 · Dec 2023 to Jun 2026
- Professional fees13 · Dec 2023 to Jun 2026
- Reportable Segment13 · Dec 2023 to Jun 2026
- Research and development expense13 · Dec 2023 to Jun 2026
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest11 · Dec 2023 to Jun 2026
- Change in fair value of Series B preferred stock tranche rights liability2 · Dec 2023 to Dec 2024
Segments
156 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 156 facts
- Reportable156 · Dec 2023 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.